Low riskFDA DrugClass III

Ascend dabigatran capsules recalled for failed impurity specification

Ascend Laboratories is recalling one lot of dabigatran etexilate 150 mg capsules. Stability testing at 12 months found out-of-specification results for Impurity II, Impurity III, and total impurities. No injuries have been reported.

From the FDA notice · Read the official notice ↗ · All Ascend Laboratories recalls

What to do

  1. Talk to your pharmacist or prescriber before stopping this medicine.
  2. Check whether your capsules are NDC 0904-7255-68, lot 25141583, expiration April 30, 2027, in a 60-count blister pack in a carton.
  3. The notice doesn't say how to get a refund or replacement; contact Major Pharmaceuticals or where you bought it.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Dabigatran Etexilate Capsules, 150 mg, 60-count (6x10) blister pack further packaged in a carton, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, INDIA, Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268, NDC 0904-7255-68.
Sold in
Nationwide
Made for
Adults (0 months and older)

This recall covers 3 products — see all of them.

Details

Units affected
3,600 cartons x 6 x 10 (in blister pack)
Illnesses reported
None reported
Manufactured in
135 Us Highway 202 206 Ste 15, N/A, Bedminster, NJ, United States
Classification
Class III
Recall number
D-0737-2026

In the FDA's words

Description
Dabigatran Etexilate Capsules, 150 mg, 60-count (6x10) blister pack further packaged in a carton, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, INDIA, Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268, NDC 0904-7255-68. Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability Lot: 25141583, Exp. April 30, 2027. Distribution: USA Nationwide Affected quantity: 3,600 cartons x 6 x 10 (in blister pack)
Hazard
Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability

3 products in this recall

The agency lists each product separately. Check every one you might have.

More from Ascend Laboratories

See all

Related topics

Industrial chemicalsOtherDrugsSold nationwideMore from FDA Drug